PLASMA PROTHROMBIN IN LIVER DISEASE: ITS CLINICAL AND PROGNOSTIC SIGNIFICANCE
Authors: G MINDRUM, H I GLUECK
Journal: Annals of Internal Medicine (1959)

Article1 June 1959PLASMA PROTHROMBIN IN LIVER DISEASE: ITS CLINICAL AND PROGNOSTIC SIGNIFICANCEGORDON MINDRUM, M.D., HELEN I. GLUECK, M.D., F.A.C.P.GORDON MINDRUM, M.D.Search for more papers by this author, HELEN I. GLUECK, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-50-6-1370 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIt is a well known clinical observation that a low concentration of plasma prothrombin which does not respond to the administration of vitamin K indicates serious liver disease.1-10 The usefulness of this observation is limited, however, by the fact that many patients with severe hepatic disease may have normal concentrations of prothrombin when the one-stage assay methods are utilized.2, 3, 5, 11, 12, 13 The two-stage procedures often detect hypoprothrombinemia in this disorder when the one-stage determination is normal or only slightly depressed.5, 13, 14, 15, 16We have made similar observations in a large group of patients with various...Bibliography1. ShapiroWeiner SM: Coagulation, thrombosis and Dicumarol, 1949, Brooklyn Medical Press, New York. Google Scholar2. Maclagen NF: Liver function tests, in Diseases of the liver (Schiff), 1956, J. B. Lippincott Company, Philadelphia. Google Scholar3. Stein HB: The "prothrombin response to vitamin K test" in the differentiation between intra-hepatic and extra-hepatic jaundice, South African J. M. Sc. 9: 111, 1944. Google Scholar4. UngerShapiro PNS: The prothrombin response to parenteral administration of large doses of vitamin K in subjects with normal liver function tests, and in cases of liver disease, standardized test for estimation of hepatic function, J. Clin. Investigation 27: 39, 1948. CrossrefGoogle Scholar5. ZiffrenOwenWarnerPeterson SECAEDFR: Hypoprothrombinemia and liver function, Surg., Gynec. and Obst. 74: 463, 1942. Google Scholar6. BiggsMacfarlane RRG: Human blood coagulation and its disorders, 1953, Charles C Thomas, Springfield, Illinois. Google Scholar7. StefaniniDameshek MW: The hemorrhagic disorders, 1955, Grune and Stratton, New York. Google Scholar8. Quick AJ: The physiology and pathology of hemostasis, 1951, Lea & Febiger, Philadelphia. Google Scholar9. De Nicola P: The laboratory diagnosis of coagulation defects, 1956, Charles C Thomas, Springfield, Illinois. Google Scholar10. LordAndrus JWWD: Differentiation of intra-hepatic and extra-hepatic jaundice, response of plasma prothrombin to intramuscular injection of Menadione, Arch. Int. Med. 68: 199, 1941. CrossrefGoogle Scholar11. PohleStewart JJK: Observations on plasma prothrombin and the effect of vitamin K in patients with liver or biliary tract disease, J. Clin. Investigation 19: 365, 1940. CrossrefMedlineGoogle Scholar12. WhiteDeutschMaddock FWES: A comparison of blood prothrombin levels with standard function tests in diseases of the liver, New England J. Med. 226: 327, 1942. CrossrefGoogle Scholar13. MannButtHurn FDHRM: Prothrombin in liver disease, clinical evaluation of the two-stage method, Gastroenterology 11: 221, 1948. MedlineGoogle Scholar14. HunterWalker RBW: Coagulation defects in liver disease, International Conference on Thrombosis and Embolism, 1955, Benno Schwabe, Basle, Switzerland. Google Scholar15. Cowling DC: Coagulation defects in liver disease, J. Clin. Path. 9: 347, 1956. CrossrefMedlineGoogle Scholar16. Orwen PA: Prothrombin and accessory factors, their clinical significance, Am. J. Med. 14: 201, 1953. CrossrefMedlineGoogle Scholar17. GlueckSherryTroll HISW(a) : Assay of plasma prothrombin with a synthetic substrate, Proc. Soc. Exper. Biol. and Med. 87: 646, 1954. (b) Glueck, H. I., Sherry, S., and Troll, W.: The utilization of a synthetic substrate (TAMe) to measure the plasma prothrombin coagulation disorders, J. Lab. and Clin. Med. 49: 41, 1957. CrossrefMedlineGoogle Scholar18. SherryTroll SW: The action of thrombin on synthetic substrate, J. Biol. Chem. 208: 95, 1954. CrossrefMedlineGoogle Scholar19. WareSeegers AGWH: Two-stage procedure for quantitative determination of prothrombin concentration, Am. J. Clin. Path. 19: 471, 1949. CrossrefMedlineGoogle Scholar20. LewisFerguson JHJH: Partial purification of human prothrombin and proconvertin, their characteristics, and interreaction, J. Clin. Investigation 32: 915, 1953. CrossrefMedlineGoogle Scholar21. ShankHoagland RECL: A modified method for the quantitative determination of the thymol turbidity reaction of the serum, J. Biol. Chem. 162: 133, 1946. CrossrefMedlineGoogle Scholar22. Hanger FM: Serological differentiation of obstructive from hepatogenous jaundice by flocculation of the cephalin-cholesterol emulsions, J. Clin. Investigation 18: 261, 1939. CrossrefMedlineGoogle Scholar23. Kunkel HG: Estimation of alterations of serum gamma globulin by a turbidimetric technique, Proc. Soc. Exper. Biol. and Med. 66: 217, 1947. CrossrefMedlineGoogle Scholar24. KunkelAhrensEisenmenger HGEHWJ: Application of turbidimetric methods for the estimation of gamma globulin and total lipids to the study of patients with liver disease, Gastroenterology 11: 499, 1948. MedlineGoogle Scholar25. DucciWatson HCJ: The quantitative determination of serum bilirubin with special reference to prompt reacting and the chloroform-soluble types, J. Lab. and Clin. Med. 30: 293, 1945. Google Scholar26. Bodansky A: Phosphatase studies. II. Determination of serum phosphatase factors influencing the accuracy of the determination, J. Biol. Chem. 101: 93, 1933. CrossrefGoogle Scholar27. MateerBaltzCommadurasSteeleBrouwer JGJIPDHHSW: Further advances in live function tests and the value of a therapeutic test in facilitating the earlier diagnosis and treatment of liver impairment, Gastroenterology 8: 52, 1947. MedlineGoogle Scholar28. Snedecor G: Statistical methods, 4th Ed., 1946, Iowa State College Press, Ames, Iowa. Google Scholar29. ArscottKoppelOlwin PMJLJH: Experience with the TAMe assay during anticoagulant therapy, J. Lab. and Clin. Med. 51: 805, 1958. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Cincinnati, Ohio*Received for publication July 3, 1958.From the Department of Medicine and the Gastric Laboratory, The University of Cincinnati, College of Medicine, and The Cincinnati General Hospital.Supported by grant H 1904 C1, Department of Health, Education, and Welfare, U. S. Public Health Service.†In previous studies employing the TAMe method, accelerator globulin was not routinely added to the activation mixture, since a severe deficiency of this factor must be present to alter the assay.17 Since such deficiencies often accompany liver disease, in the present studies .01 ml. of beef serum AC-g (Difco) was routinely added to the activation mixtures, thus obtaining optimal prothrombin yields.Requests for reprints should be addressed to Helen I. Glueck, M.D., Department of Internal Medicine, Cincinnati General Hospital, Cincinnati 29, Ohio. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byNanoparticle personalized biomolecular corona: implications of pre-existing conditions for immunomodulation and cancerThe relevance of developmental hemostasis to hemorrhagic disorders of newbornsHypoparathyroidism in Wilson's DiseaseThe relationship between conventional liver tests, quantitative function tests, and histopathology in cirrhosisSPECIFIC DETERMINATIONS OF PROTHROMBIN FOR EVALUATION OF LIVER FUNCTIONThe Hemostatic Defect of Liver DiseaseMeasurement of prothrombinBlutungen, Blutgerinnung und TransfusionEffect of high parenteral doses of vitamin-K analogs and serum albumin on the prothrombin level and liver function in alcoholic cirrhosisProtein Metabolism in Liver DiseaseThe Effect of Intravenously Administered Fat on the Coagulation MechanismHemostatic Mechanisms in Liver Disease*Coagulation defects in patients with cirrhosis of the liver undergoing portasystemic shuntsClotting Tests and other Tests of the Haemostatic Mechanism in Cirrhosis of the Liver and their Diagnostic SignificanceClinical ChemistryAlterations in indices of liver function in congestive heart failure with particular reference to serum enzymesPlasma Clotting Factors in Chronic Hepatocellular Disease 1 June 1959Volume 50, Issue 6Page: 1370-1384KeywordsAttentionBlood plasmaCirrhosisHospital medicineLiver diseasesPhosphatasesProteinsResearch laboratoriesVitamin KZinc ePublished: 1 December 2008 Issue Published: 1 June 1959 PDF downloadLoading ...